

A clinical dilemma in the detection of paediatric hypophosphataemia

Clement K.M. Ho[‡], Jun Guan Tan **Department of Pathology and Laboratory Medicine** KK Women's and Children's Hospital, Singapore

^{*}email: clement.ho@doctors.org.uk

Background

• The clinical interpretation of phosphate plasma serum or concentrations depends, to a certain extent, on the age- and genderintervals specific reference applicable the laboratory to methods employed.

 Harmonised phosphate reference intervals based on consensus have professional published by been

Results & Discussion

• Two sources of harmonised paediatric phosphate reference intervals based on consensus among healthcare professionals have been identified, i.e. the Australasian Association of Clinical Biochemists (AACB) and the Pathology Harmony Group (United Kingdom).

• There are four separate well-designed, large-scale prospective studies for the direct establishment of paediatric reference intervals for plasma/serum phosphate concentrations.

groups.

• Large-scale prospective studies have also established paediatric intervals for reference many analytes by recruiting healthy young people and using the direct method for establishing reference intervals.

Methodology

- A literature search was conducted to identify:
- (1) prospective, a priori studies for the establishment of paediatric reference intervals;
- (2) published consensus paediatric phosphate reference intervals.

• The consensus reference intervals for paediatric phosphate concentrations from the AACB and the Pathology Harmony Group are partitioned according to age but not gender.

• The Pathology Harmony Group currently recommends a single age partition for plasma and serum phosphate concentrations in both genders from 1 to 16 years of age.

• From birth up to 13 years of age, all consensus lower reference limits (LRLs) for phosphate recommended by the AACB and the Pathology Harmony Group are numerically lower than the corresponding LRLs established using direct methods in the above four prospective studies.

• The harmonised paediatric phosphate LRLs based on consensus and published by the AACB and the Pathology Harmony Group may lack diagnostic sensitivity in detecting mild to moderate hypophosphataemia especially in young children.

Lower reference limits (LRLs) for

Lower reference limits (LRLs) for

plasma/serum phosphate (mmol/L) in girls

Age group	LRLs from harmonised		LRLs established using direct methods in				Age group	LRLs from harmonised		LRLs established using direct methods in			
	reference intervals		prospective studies					referenc	e intervals	prospective studies			
	AACB	Pathology	Colantonio	Ridefelt et	Hislted et	Adeli et		AACB	Pathology	Colantonio	Ridefelt et	Hislted et	Adeli et
		Harmony	et al. 2012	al, 2012	al. 2013	al. 2015			Harmony	et al. 2012	al, 2012	al. 2013	al. 2015
		Group	(CALIPER	(Falun	(Copenhag	(CHMS			Group	(CALIPER	(Falun	(Copenhag	(CHMS
		(UK)	Study)	Study)	en Puberty	Study)			(UK)	Study)	Study)	en Puberty	Study)
					Study)							Study)	
			Abbott	Abbott	Roche	Ortho				Abbott	Abbott	Roche	Ortho
			Architect	Architect	Modular P	Vitros				Architect	Architect	Modular P	Vitros
Od to <7d	1.25	1.30	1.80				0d to <7d	1.25	1.30	1.80			
7d to <15d	1.50	1.30	1.80				7d to <15d	1.50	1.30	1.80			
15d to <1m	1.50	1.30	1.54				15d to <1m	1.50	1.30	1.54			
1m to <6m	1.45	1.30	1.54				1m to <6m	1.45	1.30	1.54			
6m to <1yr	1.30	1.30	1.54	1.64			6m to <1yr	1.30	1.30	1.54	1.64		
1yr	1.10	0.90	1.38	1.35			1yr	1.10	0.90	1.38	1.35		
2yr	1.10	0.90	1.38	1.35			2yr	1.10	0.90	1.38	1.35		
<u> </u>	1.10	0.90	1.38	1.35		1.42	3yr	1.10	0.90	1.38	1.35		1.42
4yr	0.90	0.90	1.38	1.35		1.42	4yr	0.90	0.90	1.38	1.35		1.42
5yr	0.90	0.90	1.33	1.35	1.19	1.42	5yr	0.90	0.90	1.33	1.35	1.03	1.42
6yr	0.90	0.90	1.33	1.35	1.19	1.42	6yr	0.90	0.90	1.33	1.35	1.03	1.42
/yr	0.90	0.90	1.33	1.35	1.10	1.42	7yr	0.90	0.90	1.33	1.35	1.21	1.42
8yr	0.90	0.90	1.33	1.11	1.10	1.42	8yr	0.90	0.90	1.33	1.28	1.21	1.42
9yr	0.90	0.90	1.33		1.10	1.42	9yr	0.90	0.90	1.33	1.28	1.05	1.42
	0.90	0.90	1.33		1.10	1.42	10yr	0.90	0.90	1.33	1.28	1.05	1.42
	0.90	0.90	1.55	1.11	1.00	1.10	11yr	0.90	0.90	1.33	1.28	1.06	1.23
12yr	0.90	0.90	1.02	1.11	1.00	1.10	12yr	0.90	0.90	1.33	1.28	1.06	1.23
	0.90	0.90	1.02	0.94	0.72	1.10	13yr	0.90	0.90	1.14	0.94	1.06	1.23
15vr	0.90	0.90	1.02	0.54	0.72	1.10	14yr	0.90	0.90	1.14	0.94	0.81	1.23
16vr	0.00	0.90	0.05	0.54	0.72	1.10	15yr	0.80	0.90	1.14	0.94	0.81	1.23
	0.80	0.90	0.95	0.94	0.72	0.94	16yr	0.80	0.90	0.95	0.94	0.81	0.94
	0.80	0.80	0.95	0.94	0.72	0.94	17yr	0.80	0.80	0.95	0.94	0.90	0.94

plasma/serum phosphate (mmol/L) in boys

Age group	LRLs from harmonised		LRLs established using direct methods in				Age group	LRLs from harmonised		LRLs established using direct methods in			
	reference intervals		prospective studies					reference	e intervals	prospective studies			
	AACB	Pathology	Colantonio	Ridefelt et	Hislted et	Adeli et		AACB	Pathology	Colantonio	Ridefelt et	Hislted et	Adeli et
		Harmony	et al. 2012	al, 2012	al. 2013	al. 2015			Harmony	et al. 2012	al, 2012	al. 2013	al. 2015
		Group	(CALIPER	(Falun	(Copenhag	(CHMS			Group	(CALIPER	(Falun	(Copenhag	(CHMS
		(UK)	Study)	Study)	en Puberty Study)	Study)			(UK)	Study)	Study)	en Puberty Study)	Study)
			Abbott	Abbott	Roche	Ortho				Abbott	Abbott	Roche	Ortho
			Architect	Architect	Modular P	Vitros				Architect	Architect	Modular P	Vitros
0d to <7d	1.25	1.30	1.80				0d to <7d	1.25	1.30	1.80			
7d to <15d	1.50	1.30	1.80				7d to <15d	1.50	1.30	1.80			
15d to <1m	1.50	1.30	1.54				15d to <1m	1.50	1.30	1.54			
1m to <6m	1.45	1.30	1.54				1m to <6m	1.45	1.30	1.54			
6m to <1yr	1.30	1.30	1.54	1.64			6m to <1yr	1.30	1.30	1.54	1.64		
1yr	1.10	0.90	1.38	1.35			1yr	1.10	0.90	1.38	1.35		
2yr	1.10	0.90	1.38	1.35			2yr	1.10	0.90	1.38	1.35		
<u> </u>	1.10	0.90	1.38	1.35		1.42	3yr	1.10	0.90	1.38	1.35		1.42
4yr	0.90	0.90	1.38	1.35		1.42	4yr	0.90	0.90	1.38	1.35		1.42
5yr	0.90	0.90	1.33	1.35	1.19	1.42	5yr	0.90	0.90	1.33	1.35	1.03	1.42
6yr	0.90	0.90	1.33	1.35	1.19	1.42	6yr	0.90	0.90	1.33	1.35	1.03	1.42
7yr	0.90	0.90	1.33	1.35	1.10	1.42	7yr	0.90	0.90	1.33	1.35	1.21	1.42
8yr	0.90	0.90	1.33	1.11	1.10	1.42	8yr	0.90	0.90	1.33	1.28	1.21	1.42
9yr	0.90	0.90	1.33	1.11	1.10	1.42	9yr	0.90	0.90	1.33	1.28	1.05	1.42
10yr	0.90	0.90	1.33	1.11	1.10	1.42	10yr	0.90	0.90	1.33	1.28	1.05	1.42
11yr	0.90	0.90	1.33	1.11	1.06	1.16	11yr	0.90	0.90	1.33	1.28	1.06	1.23
12yr	0.90	0.90	1.33	1.11	1.06	1.16	12yr	0.90	0.90	1.33	1.28	1.06	1.23
13yr	0.90	0.90	1.02	0.94	1.06	1.16	13yr	0.90	0.90	1.14	0.94	1.06	1.23
14yr	0.90	0.90	1.02	0.94	0.72	1.16	14yr	0.90	0.90	1.14	0.94	0.81	1.23
15yr	0.80	0.90	1.02	0.94	0.72	1.16	15yr	0.80	0.90	1.14	0.94	0.81	1.23
16yr	0.80	0.90	0.95	0.94	0.72	0.94	16yr	0.80	0.90	0.95	0.94	0.81	0.94
17yr	0.80	0.80	0.95	0.94	0.72	0.94	17yr	0.80	0.80	0.95	0.94	0.90	0.94

References:

Adeli K et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clinical Chemistry. 2015; 61(8):1049-62.

Colantonio DA et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clinical Chemistry. 2012; 58(5):854-68.

Hilsted L et al. Recommended Nordic paediatric reference intervals for 21 common biochemical properties. Scand J Clin Lab Invest. 2013; 73(1):1-9.

Ridefelt P et al. Population-based pediatric reference intervals for general clinical chemistry analytes on the Abbott Architect ci8200 instrument. Clin Chem Lab Med. 2012; 50(5):845-51.

